(1)代谢组学分析新方法开发
(2)疾病代谢调控与药物靶标发现研究

1、科研项目
(1) 国家自然科学基金青年项目，82104117，基于游离N1-甲基腺苷溯源分析的非小细胞肺癌顺铂耐药机制研究，2022-01至2024-12，30万元，在研，主持
(2) 江苏省自然科学基金青年项目，BK20210427，m1A溯源分析及其与非小细胞肺癌顺铂耐药关联研究，2021-07至2024-06，20万元，在研，主持
(3) 日本学术振兴会（JSPS）科学研究费助成事业（KAKENHI）培育项目，18H06121/19K21239，Integrative Metabolomics and Exposomics Study of Severe Asthma in Adults，2018/04-2020/03，297.7万日元，已结题，主持
2、代表性科研成果
疾病代谢调控与药物靶标发现研究：针对急性肾损伤发生率高、机制不明、缺乏有效干预手段等问题，从代谢调控角度开展了系统探索，包括：①提出了代谢组学定量计算策略，量化评价了顺铂急性肾损的代谢轮廓变化（Chem Res Toxicol, 2016）；②首次揭示了急性肾损中，肾脏皮质和髓质代谢轮廓的敏感性差异（Sci Rep, 2017）；③针对顺铂急性肾损的个体化问题，构建了肾损伤综合分级体系，建立了急性肾损个体差异预测模型 (J Proteome Res, 2017)；④针对以上研究发现的潜在调控靶标，综合利用网络药理学、分子生物学等手段，发现了若干具有临床应用前景的肾损伤干预策略（专利ZL201811091172.9; Chem Res Toxicol, 2019; Chem Res Toxicol, 2021）。

1. Li, W.; # Zhang, P.; # Hou, X.; Tang, T.; Li, S.; Sun, R.; Zhang, Z.;* Xu, F.,* Twins labeling derivatization-based LC-MS/MS strategy for absolute quantification of paired prototypes and modified metabolites. Anal Chim Acta 2022, 1193, 339399. (IF: 6.558)
2. Liao, C.; Wang, D.; Qin, S.; Zhang, Y.; Chen, J.; Xu, R.; Xu, F.;* Zhang, P.,* Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis. Frontiers in pharmacology 2022, 13, 677738.
3. Lv, B.; Xu, R.; Xing, X.; Liao, C.; Zhang, Z.; Zhang, P.;* Xu, F.,* Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics "Big Data". Metabolites 2022, 12 (6). (IF: 5.581)
4. Zhang, Y.; Wang, D.; Lv, B.; Hou, X.; Liu, Q.; Liao, C.; Xu, R.; Zhang, Y.; Xu, F.;* Zhang, P.,* Oleic Acid and Insulin as Key Characteristics of T2D Promote Colorectal Cancer Deterioration in Xenograft Mice Revealed by Functional Metabolomics. Front Oncol 2021, 11, 685059. (IF: 6.244)
5. Hou, X.; # Zhang, P.; # Du, H.; Gao, Y.; Sun, R.; Qin, S.; Tian, Y.; Li, J.; Zhang, Y.; Chu, W.; Zhang, Z.;* Xu, F.,* Prevotella contributes to individual response of FOLFOX in colon cancer. Clin Transl Med 2021, 11 (9), e512. (IF: 11.492)
6. Tang, T.; # Zhang, P.; # Li, S.; Xu, D.; Li, W.; Tian, Y.; Jiao, Y.; Zhang, Z.;* Xu, F.,* Absolute Quantification of Acylcarnitines Using Integrated Tmt-PP Derivatization-Based LC-MS/MS and Quantitative Analysis of Multi-Components by a Single Marker Strategy. Anal Chem 2021, 93 (38), 12973-12980. (IF: 6.986)
7. Tan, B.; Chen, J.; Qin, S.; Liao, C.; Zhang, Y.; Wang, D.; Li, S.; Zhang, Z.; Zhang, P.;* Xu, F.,* Tryptophan Pathway-Targeted Metabolomics Study on the Mechanism and Intervention of Cisplatin-Induced Acute Kidney Injury in Rats. Chem Res Toxicol 2021, 34 (7), 1759-1768. (IF: 3.739)
8. Zhang, P.; Carlsten, C.; Chaleckis, R.; Hanhineva, K.; Huang, M.; Isobe, T.; Koistinen, V. M.; Meister, I.; Papazian, S.; Sdougkou, K.; Xie, H.; Martin, J. W.; Rappaport, S. M.; Tsugawa, H.; Walker, D. I.; Woodruff, T. J.; Wright, R. O.; Wheelock, C. E.,* Defining the Scope of Exposome Studies and Research Needs from a Multidisciplinary Perspective. Environ Sci Tech Lett 2021, 8 (10), 839-852. (IF: 7.653)
9. Zhang, P.; Li, W.; Chen, J.; Li, R.; Zhang, Z.; Huang, Y.;* Xu, F.,* Branched-Chain Amino Acids as Predictors for Individual Differences of Cisplatin Nephrotoxicity in Rats: A Pharmacometabonomics Study. J Proteome Res 2017, 16 (4), 1753-1762. (IF: 3.950)
10. Zhang, P.; Chen, J.; Wang, Y.; Huang, Y.; Tian, Y.; Zhang, Z.;* Xu, F.,* Discovery of Potential Biomarkers with Dose- and Time-Dependence in Cisplatin-Induced Nephrotoxicity Using Metabolomics Integrated with a Principal Component-Based Area Calculation Strategy. Chem Res Toxicol 2016, 29 (5), 776-83. (IF: 3.278)